Cargando…

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

BACKGROUND: Suppressive immune cells present in tumour microenvironments are known to augment tumour growth and hamper efficacy of antitumour therapies. The amino-bisphosphonate Zoledronic acid (ZA) is considered as an antitumour agent, as recent studies showed that ZA prolongs disease-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veltman, J D, Lambers, M E H, van Nimwegen, M, Hendriks, R W, Hoogsteden, H C, Hegmans, J P J J, Aerts, J G J V
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938257/ https://www.ncbi.nlm.nih.gov/pubmed/20664588 http://dx.doi.org/10.1038/sj.bjc.6605814

Ejemplares similares

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
por: Veltman, Joris D, et al.
Publicado: (2010)

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
por: Duivenvoorden, W C M, et al.
Publicado: (2007)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
por: Veltman, Joris D., et al.
Publicado: (2010)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
por: Cornelissen, Robin, et al.
Publicado: (2014)

New Roads Open Up for Implementing Immunotherapy in Mesothelioma
por: Cornelissen, R., et al.
Publicado: (2012)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
por: Mahaweni, Niken M., et al.
Publicado: (2013)

Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
por: Horie, N, et al.
Publicado: (2007)

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
por: Yamamoto, J, et al.
Publicado: (2014)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer
por: Su, Y, et al.
Publicado: (2010)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
por: Arnold, David T, et al.
Publicado: (2017)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts
por: Liu, J, et al.
Publicado: (2007)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models
por: Jarzabek, M A, et al.
Publicado: (2014)

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
por: Walters, M J, et al.
Publicado: (2014)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
por: Reed, M D, et al.
Publicado: (2013)

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model
por: Julien, S, et al.
Publicado: (2009)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
por: Jacobson, B A, et al.
Publicado: (2009)

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
por: den Brok, M H M G M, et al.
Publicado: (2006)

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005)

Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
por: Alì, G, et al.
Publicado: (2009)

Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
por: Bertrand, Y, et al.
Publicado: (2011)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_po7qk3pc686kvi52s25auoob4r